China’s BeiGene pitches a $150M IPO to fund its cancer pipeline

Damian Garde Chinese biotech BeiGene is hoping to trade on the Nasdaq, filing for an IPO worth more than $ 150 million to support its pipeline of targeted cancer drugs. FierceBiotech ...

Roche blindsided by off-label Avastin fallout in India

Emily Wasserman Roche, maker of pricey wet age-related macular degeneration drug Lucentis, has long railed against countries' moves to use its cancer drug Avastin off-label for ...

Akorn estimates it overstated ’14 financials by $35M

Carly Helfand Last April, Illinois-based Akorn Pharmaceuticals told shareholders it had likely overstated its financial results for the last three quarters of 2014–an announcement ...

Theracos raises $25M to take on Big Pharma in diabetes

Damian Garde Marlborough, MA's Theracos raised $ 25 million to support its work on a safer version of a common treatment for Type 2 diabetes. FierceBiotech News

Celgene names Mark Alles to CEO position, ending internal contest

Alok Saboo In this week's Chutes and Ladders, Celgene named Mark Alles as CEO, Baxalta CEO Ludwig Hantson will leave following the Shire merger, and MannKind appointed Matthew Pfeffer ...

Hemophilia marketing tactics raise questions as market heats up

Carly Helfand While there are plenty of drugs for hemophilia, new patients can be few and far between. To build their market share, some drugmakers and specialty pharmacies have begun ...

Pfizer looks to cut the line in CAR-T with off-the-shelf approach

Damian Garde Pfizer, breaking into the field of re-engineered T cells for cancer, believes its work with partner Cellectis could eventually top the efforts of more advanced rivals including ...

Local council moves to buy Novartis’ Horsham site with view to creating science park

Nick Paul Taylor Novartis is on the verge of offloading its former R&D site in Horsham, U.K., to the local council. The agreement of initial terms with West Sussex council ...

Investors look for Pfizer, Allergan, Mylan, Baxalta and others to address big questions at JP Morgan conference

Eric Palmer There are big questions facing some of pharma's key players this year, like whether the Pfizer and Allergan deal will get done and why Allergan thinks that is its best ...

Medicaid would have saved $1.4B with discounts for generics: Report

Emily Wasserman Sen. Bernie Sanders (I-VT) and Rep. Elijah Cummings (D-MD) can add some ammo to their drug price-fighting arsenal, as a new report shows that Medicaid could have saved ...

Shire and longtime target Baxalta meeting to talk takeover: Bloomberg

Carly Helfand Shire has refused to give up on target Baxalta, which first rejected it 5 months ago. And its persistence may finally be paying off. FiercePharma News

Pfizer nabs speedy FDA review for new use of lung cancer med Xalkori

Carly Helfand Pfizer's Xalkori is already used to treat patients with metastatic non-small cell lung cancer whose tumors are ALK-positive. But now it's on its way to snagging ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS